SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Incorporating β2-microglobulin and β-trace protein filtration markers may improve GFR estimation in patients with solid tumors. Adding the novel endogenous filtration markers β2-microglobulin and ...
Patritumab deruxtecan showed no overall survival benefit over chemotherapy in EGFR mutation-positive NSCLC patients. The drug demonstrated a slight progression-free survival advantage and higher ...
Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic ...
CAMBRIDGE, Mass., Oct. 26, 2022 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of ...
Bispecific antibody targeting of CD47/CD19 to promote enhanced phagocytosis of patient B lymphoma cells. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does not ...
DEAR DR. ROACH: I am a 73-year-old female. A recent blood test returned an eGFR (estimated glomerular filtration rate) of 59. My physician’s nurse told me that the test was normal. When I asked her ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback